Keep up the good work. My first ever meter was a GlucoMen Visio and that served me well
Customer Email April 2013I wish to thank your customer service for the very good service given on my recent call to them. They were very efficient and helpful, thank you again
Customer Email March 2013Your service was unbelievable, got a call back next morning and received the new case the next day. Perfect! thanks for all your help . I'm Type 1 so i will be with you forever. You really know how to treat customers.One less thing to worry about.
Customer Email October 2012Brilliant - Truly amazing machine, so easy to use and would recommend them to any diabetic
Customer Email - Aug 2012Thank you - Received my new meter on Saturday. Thank you for the quick and no fuss service
Customer Email - Aug 2012Thank you for sending my GlucoMen system. I appreciate the quick results, less pain and smaller samples needed and have quickly learnt how to use it
Customer Email - 2012
A new position paper from leading diabetes societies calls for add-on therapy within 3 months if patients do not reach glycaemic goals, and represents a significant shift away from current NICE guidelines.
The European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) joint position statement calls for a more patient-centred approach which allows medication choice to be more open than currently recommended by NICE. The new approach encourages use of a range of diabetes therapies that are currently used third of fourth line, such as exenatide, gliptins and basal insulin.
The statement highlights the need to allow for individual patient's needs, preferences and tolerances, and to take into account that type 2 diabetes patients differ substantially in terms of age, disease progression and co-morbidities. At the same time it aims to be less prescriptive as there is little evidence to distinguish the effectiveness of therapy options following metformin.
The significant cost implications of such an approach will be reviewed in future NICE guidelines on the management of type 2 diabetes. Current NICE 2009 guidelines for diabetes recommend sulphonylureas are used second line, with new oral therapies reserved for when there is a particular risk of hypoglycaemia or the patient does not tolerate, or has a contraindication to, sulphonylureas. Use of insulin is recommended only if HbA1c levels remain high after using other treatments.
The study can be viewed on the EASD website from the link below.
Information Source
European Association for the Study of Diabetes (EASD) - http://87.234.226.93/easd_intranet/easdwebfiles/statements/type2guidelines/type2guidelines.html
.jpg)
Play GlucoMen Diabetes Education Videos
.jpg)
GlucoMen LX PLUS blood glucose and ketone monitor
